BioNTech SE’s Post

Meet #ivonescimab, Akeso's cancer-fighting superstar! 🌟 — It just crushed the competition in a head-to-head Phase 3 clinical trial, outperforming #pembrolizumab! 🏆 💪 Ivonescimab, discovered by Akeso, is a first-in-class tetravalent PD-1/VEGF bispecific antibody engineered with Akeso's Tetrabody technology. It displays unique cooperative binding to each of its intended targets consistent with increased in vitro functional bioactivities compared with VEGF or PD-1 alone. Importantly, the Fc-null IgG1 design resulted in reduced FcgR interactions and minimal ADCC, ADCP activities consistent with its clinical immunosafety profile. 🧬 Curious about its mechanism of action? 🧬 🎥Check out this video for an in-depth look! 🎥 #bispecific #immunotherapy #IO #cancer #VEGF #science #Akeso #ivonescimab

Anybody who has watched a loved one battle with cancer will know what a mixed blessing #Chemotherapy can be. Which is why so much hope - and money - has been invested in Antibody Drug Conjugates (ADCs), which can be far more targeted and less toxic, but which are also far more expensive at the moment. My colleague Cecilia Boz, PhD summarises the debate around ADCs here, explaining clearly not only what the potential of this relatively new technology is, but also why ADCs may fall short of the hype. Can ADCs become the accepted Standard of Care in place of chemo? Or are they at best a stepping stone - at worst a diversion - on the road towards more significant breakthroughs? #Cancer #Pharmaceuticals https://lnkd.in/ebQBsUvV

We're proud to announce the publication of very promising pre-clinical data for our next generation PD-1/PD-L1 bispecific antibody, CTX-8371, in the journal OncoImmunology. CTX-8371 outperformed approved checkpoint inhibitors in a series of in vitro and in vivo preclinical experiments. In addition, the data reveal synergistic activity of the combination of CTX-8371 and the Compass CD-137 agonist, CTX-471. The preclinical data supported the acceptance of our US IND submission and we are excited to treat the first patients with CTX-8371 in Q1 2024. Read our entire announcement at https://bit.ly/3TbhFqh. #CMPX #oncoimmunology #checkpointinhibitor #immunotherapy #cancerresearch #bispecificantibody #biotech #biotechnology #cancer #healthcare

Nature Reviews Drug Discovery at Springer Nature Group and Nature Portfolio highlights the latest publication of our co-founders Luis Alvarez-Vallina and Belén Blanco Durango on STAb Technology for the treatment of #multiplemyeloma. This research highlight recaps the most relevant results obtained in the preclinical study showing the superiority of STAb-TBCMA compared to CAR T cells against the same target. As our co-founder underscores in the research highlight: “In this strategy, T cell recruitment is not restricted to engineered T cells (…). The polyclonal recruitment by TCEs of both engineered and unmodified bystander T cells, present at the tumour site, lead to a significant boost in antitumour T cell responses”. We are eager to continue the development of our product STAb-TBCMA and the development of our #STAbTechnology for other cancer types. You can access the Research Highlight here: https://lnkd.in/duXK4BJE For the original paper on STAb-TBCMA: https://lnkd.in/e38ugSjW   #immunotherapy #cancertherapeutics #multiplemyeloma #immunooncology #celltherapy

🎖Check out the Highly cited #Review "Targeted Therapy and Mechanisms of Drug Resistance in Breast Cancer" 👋by Briana Kinnel (Morehouse School of Medicine) et al. 📌Access the full paper here: https://lnkd.in/dPab5v5R Keywords: drug resistance; MDR; HER2; iNOS; aryl hydrocarbon receptor; PTK6; CDK4/6; Wnt/β-catenin

Yesterday was a monumental day for #cancer patients and for Strand Therapeutics. STX-001, the first-ever programmable mRNA therapy, entered the clinic in a Phase 1 trial for solid tumors. Programmable mRNA therapies are based on groundbreaking technology with the potential to transform the treatment of cancer and other diseases. To learn more, read on! (And if your at #ASCO, check out Strand's poster.) #mRNA #ASCO2024 #ASC024

Adjuvant therapy and combination therapy leverage the strengths of different treatments to provide a more robust and comprehensive approach to cancer care. By targeting multiple pathways, reducing resistance, lowering dosages, and addressing tumor heterogeneity, these strategies offer improved efficacy and outcomes compared to mono-therapy. Below is an example!

#LearningUpdate This month, we’re diving into the fascinating world of monoclonal antibodies! These crucial tools are making waves in cancer treatment and diagnostics. 🧠 Ready for a challenge? What do you think is required for the production of a monoclonal antibody reagent in a blood bank laboratory? 🔍 Type your answer below! Let’s see who’s got the right knowledge! 💬 #MonoclonalAntibodies #MonthlyQuiz #ScienceLearning

#China #NMPA accepts #Anheart #Therapeutics and #Innovent's second #NDA for #taletrectinib to treat #ROS1-positive #lung #cancer. The Center for Drug Evaluation of China’s National Medical Products Administration has accepted a second New Drug Application for #taletrectinib as a first-line treatment for ROS1-positive non-small cell #lungcancer (#NSCLC). This milestone underscores the potential of taletrectinib as a transformative medicine for patients with advanced or metastatic ROS1-positive NSCLC, supported by positive results from the #TRUST-I trial. #Shantipharmaceuticals